T
TIBEAY BioSciences
First-in-class therapy for acute traumatic brain injury.
About TIBEAY BioSciences
TIBEAY BioSciences B.V. is a Dutch clinical-stage biotechnology company developing therapies for acute neurological conditions. The company is focused on its lead candidate, Ronopterin, a first-in-class small molecule designed for the early treatment of moderate to severe traumatic brain injury (TBI). TBI is a leading cause of death and long-term disability worldwide, with an estimated 50 million new cases annually, yet there are no approved pharmacological therapies that specifically target its secondary injury mechanisms.
TIBEAY's therapeutic approach with Ronopterin targets the secondary damage that occurs after the initial trauma. The drug is a selective inhibitor of inducible nitric oxide synthase (iNOS), an enzyme that becomes highly expressed after a brain injury and contributes to the formation of neurotoxic radicals. By selectively inhibiting iNOS, Ronopterin aims to reduce this progressive tissue damage, improve neurological outcomes, and enhance the quality of life for patients. This biological pathway's significance was previously recognized by a Nobel Prize in Physiology or Medicine.
Founded in the Netherlands, the company is advancing Ronopterin into late-stage clinical development. In April 2026, TIBEAY Biosciences announced it had raised €35 million in a financing round led by ATHOS KG, with participation from MIG Capital, Meneldor, and Oost NL. The proceeds are intended to fund a European, multicenter Phase 3b registrational trial. This pivotal study is designed to form the basis for a future marketing authorization application with the European Medicines Agency (EMA). The funding will also support the manufacturing of clinical supplies, supply chain preparation, and other regulatory and operational activities.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Apr 2026 | $39M | $154M | Oost NL - Eastern Netherlands Regional Development Agency · Meneldor · Athos · MIG Capital | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Neurofold TherapeuticsSmall-molecule therapeutics targeting neurodegenerative protein aggregates. |
Greenwood Village, United States | Operational | — | — | — |
SomatoceuticsPeptide nanotubes for targeted therapeutic drug delivery. |
Mount Pleasant, United States | Operational | |||
| Perth, Australia | Operational | ||||
Nuvie BioPeptide antagonist for acute migraine treatment. |
— | Operational | |||
Aluco BioSciences Inc.Tailored compounds for neurological and endocrine diseases. |
— | Operational | |||
GlymphGlymphatic system therapeutics for neurological diseases. |
— | Operational | |||
Ormoni BiosciencesAI-driven platform for industrializing peptide drug development. |
Boston, United States | Operational | |||
Aura Biolabs Inc.Migraine therapeutic identification platform for pharmaceutical partners. |
Provo, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
TIBEAY BioSciences in the Nijmegen ecosystem
The TIBEAY BioSciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- ATAthos
Oost NL - Eastern Netherlands Regional Development Agency
Meneldor
MIG Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TIBEAY BioSciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TIBEAY BioSciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








